Blueprint library/Peptides

Peptide Manufacturing Software for GLP-1 & Synthetic Peptide APIs

Peptide manufacturing. Every residue, coupling, fraction, pool, and impurity in one lineage.

Run solid- and liquid-phase peptide synthesis, fragment condensation, cleavage, deprotection, purification fractions, pooling, conjugation, counterion exchange, drying, analytical control, mass balance, and release.

Sequence-to-container peptide lineage
The molecular version controls residue-level execution; fractions and pools remain physical, quantitative records.
A controlled peptide sequence expanding through synthesis cycles, fractions, pooling and conjugated API containers
Sequence
Chirality, protection, modification and conjugation are structured authority.
Cycles
Actual lots, parameters, repeats and source runs attach to each residue position.
Fractions
Included and excluded material stays visible in genealogy and mass balance.
API
Pool contribution and conjugation lead to exact released containers.

Synthetic peptide manufacturing turns a controlled molecular definition into a physical lineage through repeated chemistry, selective transformations, difficult separations, and quantity decisions. The final API must trace to sequence, stereochemistry, protecting groups, resin, amino-acid lots, cycles, fragments, fractions, pools, conjugates, analytical methods, and every loss or rework.

Seal represents that lineage directly. It does not force peptide manufacture into a generic recipe that knows only “reaction,” “purification,” and “release.”

01

The molecular definition is the manufacturing authority

Sequence, direction, amino-acid identity, chirality, non-natural residues, modifications, termini, disulfide pattern, conjugation site, salt or counterion, molecular formula and mass, structure, impurity strategy, specifications, methods, and lifecycle state form the approved product definition.

Structured positions support recipe generation, expected mass, material calculation, sequence-related impurity naming, and independent verification. A rendered sequence remains a view, not the sole source of truth.

Sequence-to-container peptide lineage
The molecular version controls residue-level execution; fractions and pools remain physical, quantitative records.
A controlled peptide sequence expanding through synthesis cycles, fractions, pooling and conjugated API containers
Sequence
Chirality, protection, modification and conjugation are structured authority.
Cycles
Actual lots, parameters, repeats and source runs attach to each residue position.
Fractions
Included and excluded material stays visible in genealogy and mass balance.
API
Pool contribution and conjugation lead to exact released containers.
Fig. 1 / The controlled sequence expands through residue-specific synthesis and converges through fractions, pooling, conjugation, and final API release
02

Sequence versions are controlled independently of batches

Draft, reviewed, approved, effective, superseded, and retired definitions retain comparison, signatures, intended products, process applicability, and regulatory state. Changes highlight substitution, insertion, deletion, stereochemistry, protection, modification, and conjugation differences.

An active batch cannot resolve an unapproved molecular version. A change can assess in-process material and future campaigns separately.

03

Manufacturing strategy selects the right route

Solid-phase synthesis, liquid-phase synthesis, hybrid approaches, protected fragments, fragment condensation, recombinant inputs, late-stage conjugation, and product-specific transformations can use different configured paths.

The route defines intermediates, isolations, controls, holds, and impurity risks without losing common sequence and genealogy principles.

04

Recipe generation is deterministic and independently checked

The effective sequence, scale, resin loading, protection strategy, chemistry, and process version generate ordered cycles, materials, stoichiometry, parameters, expected consumption, washes, repeats, and equipment method.

Generator version, inputs, checksum, manual overrides, review, and approval remain visible. The batch instruction is reconciled with the molecular definition before execution.

05

Raw materials have residue- and operation-specific purpose

Protected amino acids, resin and linker, coupling reagents, bases, deprotection agents, scavengers, cleavage reagents, solvents, catalysts, buffers, conjugates, and membranes retain identity, grade, chirality, purity, water or other critical attributes, lot, status, storage, expiry, and open life.

Actual issue connects each lot to the residue, cycle, fragment, or transformation where used. A later supplier alert can find exact sequence positions and final containers exposed.

06

Synthesis captures cycle performance without copying the controller

The synthesizer or reactor system can remain authoritative for dense valve actions, flows, and signals. Seal records cycle identity, residue position, intended chemistry, material lots, key parameters, monitoring response, alarms, holds, repeats, deviations, source data, and acceptance.

One recipe. Many views.
PD bench, master batch record, MSAT model, CMO record, and Module 3 are renderings of the same structured graph — not separate documents that drift.
Recipe graph
unit operations / CPPs / CQAs / raw materials
cell line lineage / validation / versioned / live
PD view
design space / ranges
scale-down model qualification
Master batch record
executable / approved limits
21 CFR 11 signatures
MSAT model
CPV trends / campaign learnings
deviation history / live
CMO batch record
inherited via transfer
site deltas explicit
Module 3 (CMC)
3.S.2.2 / 3.S.2.4 / 3.S.2.5
rendered, not assembled
Every team queries the same node
Fig. 2 / The approved recipe, automation evidence, accountable operation, material state, sample, and decision remain connected

A repeated coupling preserves the first attempt and its evidence. It cannot silently shift the remaining sequence or overwrite consumption.

07

Fragments retain independent identity before condensation

Each protected or partially deprotected fragment has molecular definition, source synthesis, terminal state, quantity, purity, container, storage, hold, tests, and disposition. Condensation records actual stoichiometry, activation, additions, conditions, yield, and resulting lineage.

Many-to-one convergence remains explicit. A fragment-specific concern can trace forward to every derived pool and API container.

08

Cleavage and deprotection create governed chemical states

Resin or support, reagent composition, time, temperature, mixing, washes, transfers, precipitation, recovery, and deprotection conditions remain connected to the synthesis lot. The crude product receives identity, quantity, concentration or solids basis, container, quality state, and hold.

Partial deprotection, staged cleavage, oxidation or folding, and product-specific quench paths retain their own transformations and controls.

09

Purification fractions are material, not rows in a report

Chromatography load, column, packing, resin cycle, mobile phases, gradient, detector signals, fractions, volumes, concentrations, purity, identity, impurity profile, containers, and status form one record.

Discarded, held, pooled, reprocessed, and investigation fractions remain in genealogy and mass balance. Chromatographic interval and source data stay linked to the physical container.

10

Pooling is a scientific decision with quantity consequences

The plan defines eligible fractions and preliminary criteria. Actual inclusion or exclusion records identity, purity, critical sequence impurities, concentration, volume, molar or mass contribution, rationale, reviewer, and recalculated pool state.

Chromatographic evidence, fraction-specific quality, contribution, exclusion rationale, and resulting pool quantity reach one controlled decision
Fig. 3 / Chromatographic evidence, fraction-specific quality, contribution, exclusion rationale, and resulting pool quantity reach one controlled decision

A pool amendment creates a versioned decision; it never edits the original selection after downstream processing begins.

11

Conjugation, cyclization, and folding preserve precursor lineage

Fatty-acid or other conjugation, linker activation, ligation, cyclization, disulfide formation, folding, quench, purification, and residual removal connect precursor lots, stoichiometry, conditions, samples, yields, and analytical evidence.

Positional isomers and incomplete reaction products remain tied to the exact molecular and process versions used to define them.

12

Desalting, counterion exchange, and concentration track chemical basis

Membrane, cassette, buffer, exchange cycles, conductivity, pH, concentration, volumes, solvent transition, counterion, yields, integrity, samples, and holds remain part of the lineage.

Quantity basis stays explicit: peptide free base, salt form, dry content, assay-corrected mass, net peptide content, or molar amount. Conversions retain formulas, units, source values, precision, and review.

13

Drying and final handling preserve physical state

Lyophilization, precipitation, filtration, drying, milling, sieving, subdivision, and packaging record equipment, recipes, containers, environment, exposure, conditions, samples, yields, and reconciliation.

Final containers retain identity, quantity basis, label, storage, sample withdrawals, status, use, shipment, and downstream drug-product genealogy.

14

Analytical control resolves peptide-specific impurities

Identity, assay, purity, sequence variants, deletion and insertion peptides, truncated species, epimers, racemization, deamidation, oxidation, aggregation, protecting-group residues, conjugate species, residual solvents, water, counterion, bioburden, and endotoxin attach to exact material states.

Methods retain sample preparation, molecular reference, instrument, raw data, integration or deconvolution, standards, impurity nomenclature, calculation, specification, and review.

15

Mass balance is chemistry-aware

The batch reconciles theoretical loading, resin substitution, amino-acid and reagent use, crude recovery, fragment quantities, fraction contributions, pool amount, samples, rework, waste, dry content, counterion, assay correction, final containers, and yield.

Mass, moles, peptide content, and solution volume are not treated as interchangeable. Unexplained differences open assessment before release.

16

Cleaning and campaign state reflect peptide carryover risk

Synthesizers, reactors, filters, columns, tanks, dryers, mills, and tools retain product-contact history, cleaning procedure, sequence- or potency-related residue target, analytical method, limits, results, and release.

Highly potent peptides, conjugates, and difficult-to-clean modifications can require dedicated or campaign controls. Actual equipment state gates the next product.

17

Release joins molecular, chemical, analytical, and quantity evidence

Disposition reconciles molecular version, route, generated recipe, material lots, cycle evidence, fragments, cleavage and deprotection, fractions, pool decisions, conjugation, final processing, analytical results, mass balance, holds, deviations, cleaning, containers, and stability obligations.

The EMA's guideline on development and manufacture of synthetic peptides addresses modality-specific manufacturing and control considerations. Seal organizes the executable evidence while manufacturer science and registered strategy remain authoritative.

18

Source systems retain automation and analytical depth

Synthesizer controls, chromatography data systems, mass spectrometry software, and process historians should retain native high-frequency or vendor-specific evidence. Seal references or captures what is needed to contextualize the batch and decision.

It owns molecular-to-container genealogy, controlled recipe resolution, material purpose, physical fractions and pools, cross-system completeness, quality workflows, and disposition.

19

Where Seal is strongest

Seal is strongest when sequence and chemistry must remain connected to physical material and quality decisions. Because residue positions, material lots, cycles, fractions, pools, methods, impurities, and containers are related objects, forward and backward impact analysis is immediate.

A conventional MES can execute ordered steps; a LIMS can report purity. Seal's advantage is preserving why this batch, with these residue-level inputs and fraction decisions, became these released API containers.

20

Prove one sequence-to-container campaign

The first implementation should follow one modified peptide from approved sequence through generated recipe, resin and amino-acid issue, synthesis cycles, a repeated coupling, cleavage, purification fractions, pool amendment, conjugation, counterion exchange, drying, testing, mass balance, containers, cleaning, and release.

Include a wrong bottle-position scan, low coupling response, fragment failure, out-of-hold crude, borderline epimer fraction, amended pool, membrane-integrity failure, impurity integration change, assay-corrected discrepancy, and post-release amino-acid alert. The model is ready when each final container reconstructs every residue, transformation, fraction, and decision.

Operating model

Native control model
States and decisions owned by this blueprint
06 native controls
Molecular & Sequence Control
Residues, chirality, protection, modifications, termini, conjugation sites, structures, checksums, comparisons, and approvals govern manufacture.
Deterministic Recipe Generation
Approved sequence, scale, resin, protection, and chemistry generate cycles, materials, stoichiometry, parameters, checksums, and independent review.
Residue-Level Synthesis Evidence
Every position retains actual lots, quantities, parameters, response, alarms, holds, repeats, source data, acceptance, and operator decisions.
Fragments, Fractions & Pools
Independent fragment lineages, chromatographic fractions, impurity profiles, selected contributions, exclusions, rework, and resulting pools remain physical records.
Chemistry-Aware Mass Balance
Resin loading, molar inputs, crude recovery, fraction contributions, losses, assay correction, net peptide, samples, waste, and containers reconcile.
Sequence-to-Release Genealogy
Molecular version, recipe, materials, cycles, intermediates, fractions, pools, methods, equipment, cleaning, containers, and disposition remain traversable.
Connected foundations
Existing blueprints supplying governed records and execution
07 foundations
cmcCMC Data & Module 3 Content Management Software
Connect product definitions, processes, specifications, methods, characterization, validation, stability, claims, CTD sections, market variants, review, and post-approval change without rebuilding truth in documents.
mesPharmaceutical MES & Manufacturing Execution Software
Seal captures the batch as it runs. AI-configured workflows evolve with your process. Unified with LIMS, QMS, and ELN.
APIAPI Manufacturing Software
Electronic batch execution and genealogy across raw materials, reactions, intermediates, equipment, process testing, quality, and release.
EBRElectronic Batch Record Software
Author, execute, review, and release GMP batch records with material and equipment checks, automated data capture, controlled exceptions, and complete history.
limsPharmaceutical QC LIMS Software
Seal checks results against live specs. AI-configured methods evolve with your process. Unified with MES, QMS, and ELN.
sdmsScientific Data Management System (SDMS) Software
Automatically capture scientific instrument and application data, preserve original files and metadata, prove file-set completeness and integrity, connect data to samples and work, govern review and derived versions, search across formats, retain and restore records, and manage migrations and legal holds.
BRPharmaceutical Batch Review & Release Software
Plan batch-release evidence from the approved product state, review execution and testing concurrently, resolve exceptions, control market eligibility, generate CoAs, and sign an accountable disposition.
Peptide Manufacturing Software for GLP-1 & Synthetic Peptide APIs owns the operating state above; connected foundations remain authoritative for their specialized records.

Capabilities

Residues, chirality, protection, modifications, termini, conjugation sites, structures, checksums, comparisons, and approvals govern manufacture.
Approved sequence, scale, resin, protection, and chemistry generate cycles, materials, stoichiometry, parameters, checksums, and independent review.
Every position retains actual lots, quantities, parameters, response, alarms, holds, repeats, source data, acceptance, and operator decisions.
Independent fragment lineages, chromatographic fractions, impurity profiles, selected contributions, exclusions, rework, and resulting pools remain physical records.
05EBRconnected foundationConjugation & Final Processing
Precursor lots, stoichiometry, reactions, folding, exchange, concentration, drying, containers, corrected quantities, and yields stay connected.
06limsconnected foundationPeptide Analytics
Identity, assay, sequence variants, epimers, truncations, conjugate species, aggregates, residuals, water, counterion, and source evidence attach to exact states.
Resin loading, molar inputs, crude recovery, fraction contributions, losses, assay correction, net peptide, samples, waste, and containers reconcile.
Molecular version, recipe, materials, cycles, intermediates, fractions, pools, methods, equipment, cleaning, containers, and disposition remain traversable.

Entities

Entity
Description
Kind
C
Peptide Product
Sequence, structure, modifications, conjugates, process, quality attributes, specifications, and release.
type
C
Lipidated GLP-1 Peptide API
Sequence, modifications, conjugation site, process, impurity strategy, controls, and release pattern.
template
C
GP-42 Peptide API
Approved 39-residue lipidated peptide with effective molecular and process versions.
instance
CB
Peptide Sequence
Position-level residue, chirality, protection, modification, termini, version, checksum, and approval.
type
CB
Position-Controlled Peptide Sequence
Residue, chirality, protection, modification, conjugation site, notation, checksum, and approval.
template
CB
SEQ-GP42 v07
Effective molecular definition used for commercial batch GP42-026.
instance
FR
Synthesis Recipe
Generated cycles, fragments, materials, stoichiometry, parameters, repeats, generator, and approval.
type
FR
Solid-Phase Peptide Synthesis
Resin loading, deprotection, coupling, capping, washes, monitoring, repeats, and cleavage.
template
FR
SPPS-GP42-026
Reviewed recipe generated from SEQ-GP42 v07 for the 4 mol scale.
instance
F
Peptide Material
Amino acid, resin, reagent, solvent, buffer, conjugate, catalyst, or membrane lot and state.
type
R
Synthesis Cycle
Residue position, chemistry, actual materials, parameters, response, alarm, repeat, and acceptance.
type
WC
Peptide Intermediate
Protected fragment, resin-bound, crude, deprotected, conjugated, folded, exchanged, or dried material.
type
TA
Purification Fraction
Chromatographic interval, container, quantity, identity, purity, impurity profile, and state.
type
TA
Preparative Peptide Fraction
Interval, chromatogram, container, quantity, identity, purity, epimers, variants, and state.
template
TA
GP42-026 / Fraction 22
Borderline D-isomer fraction held outside the approved pool.
instance
MT
Peptide Pool
Included fractions, contributions, rationale, quantity basis, quality, hold, and status.
type
MT
Approved Peptide Purification Pool
Eligible fractions, contributions, exclusions, rationale, corrected quantity, tests, hold, and approval.
template
MT
POOL-GP42-026-P2
Approved post-conjugation pool with complete source-fraction and quantity lineage.
instance
LT
Peptide Test
Identity, assay, purity, sequence impurity, epimer, conjugate, residual, physical, or microbial evidence.
type
E
Peptide API Lot
Final material, containers, corrected quantities, specification, release, storage, and genealogy.
type

FAQ

A connected operation needs molecular control, recipe generation, MES, automation data, residue-level material genealogy, fraction and pool management, LIMS, equipment and cleaning control, quality workflows, mass balance, and batch disposition.
Yes. Sequence, non-natural residues, modifications, lipid or other conjugation, solid- or liquid-phase synthesis, purification, peptide-specific impurities, final physical form, and release can be configured to the actual product.
The approved position-level definition and route are processed by a versioned generator to create cycles, material positions, stoichiometry, parameters, expected consumption, instrument method, and checksum for independent review.
Yes. Solid-phase cycles, solution-phase transformations, fragment manufacture, condensation, hybrid routes, and product-specific branches use common molecular, material, genealogy, and decision controls.
The original attempt, material use, monitoring response, parameters, alarm or decision, authorization, repeat, and downstream sequence remain visible. A repeat never overwrites the first event.
Each fraction has source interval, container, quantity, identity, purity, sequence impurity profile, status, and genealogy. Pool decisions retain contributions, exclusions, rationale, and corrected totals.
Yes. Precursor and conjugate lots, activation, stoichiometry, additions, conditions, quench, purification, samples, yields, residuals, site specificity, and confirmation remain connected.
Impurity identity and nomenclature link to molecular version, process step, sample, method, raw data, integration or deconvolution, result, specification, investigation, and pool or release decision.
Yes. Moles, free-peptide mass, salt form, net peptide content, dry content, assay-corrected mass, solution volume, and configured conversions retain units, formulas, source values, and review.
No. Controllers remain authoritative for detailed equipment actions and high-frequency signals. Seal retains batch, cycle, material, exception, source reference, completeness, and accountable decision context.
Actual use by residue, cycle, fragment, or operation enables forward tracing from an amino acid, resin, reagent, solvent, membrane, or conjugate lot to affected fractions, pools, API containers, and downstream batches.
Trace one approved sequence through recipe generation, all material issues and cycles, a repeat, cleavage, fractions, pool amendment, conjugation, final processing, peptide analytics, mass balance, containers, and release.

Related blueprints

ContinuousContinuous Pharmaceutical Manufacturing Software

Material moves through time. Every disturbance, residence window, control action, diversion, collection, and batch boundary reconstructed.

Operate continuous drug-substance and drug-product processes with time-based material genealogy, residence-time distributions, process-state classification, PAT and active controls, disturbance management, diversion, collection, batch definition, review, validation, and release.

InhalationInhalation Drug Product Manufacturing Software

Formulation and device are one delivered-dose system. Every material attribute, component lot, assembly state, aerosol test, and release decision connected.

Run metered-dose inhaler, dry-powder inhaler, nebulized solution and suspension manufacturing with formulation and device configuration, component genealogy, filling and assembly, conditioning, delivered-dose and aerodynamic testing, stability, investigations, and release.

msatMSAT Process Knowledge & Manufacturing Support Software

Development intent to manufacturing reality. Every signal, investigation, change, and transfer strengthens the process model.

Run Manufacturing Science and Technology across process ownership, technology transfer, site and product knowledge, batch monitoring, process signals, investigations, change impact, validation and CPV, improvement, comparability, commitments, and governed manufacturing support.

PAT / RTRTPharmaceutical PAT & Real-Time Release Testing Software

Process signal to quality prediction. Prediction to an authorized release decision.

Govern PAT methods, sensors, chemometric models, calibration sets, predictions, process actions, model lifecycle, RTRT strategies, fallback testing, and batch-release evidence.

LyophilizationPharmaceutical Lyophilization & Freeze-Drying Cycle Management Software

Filled vial to dried cake. Every load position, phase transition, alarm, and release decision connected.

Govern lyophilization recipes, product and load configurations, loading and stoppering, chamber readiness, source cycle data, endpoints, exceptions, unload genealogy, quality results, validation, and release.

PVPharmaceutical Process Validation & PPQ Software

Approved process to executable protocol. PPQ evidence to continued verification. Every claim traceable to source.

Plan and execute process performance qualification, govern readiness and acceptance criteria, connect manufacturing and laboratory evidence, resolve deviations, calculate capability, approve validation conclusions, and hand the proven process into continued verification.

Go live in 48 hours.